GM-CSF even constitutes the sole agent for treating prostate cancer and melanoma as it is responsible for the survival and differentiation of myeloid cell progenitors and immune enhancement of cytokine secretion, aiding antigen presentation and lymphocyte-based immunity (Hamilton 2019; Lotfi et al. 2019). This evidence concerns the gene CSF2 and prostate cancer.